Guidance for Industry InternetSocial Media latforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drug s and Medical Device s DRAFT GUIDANCE This guidance - Pdf
246K - views

Guidance for Industry InternetSocial Media latforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drug s and Medical Device s DRAFT GUIDANCE This guidance

Published byalida-meadow

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Sub

Tags : Comments and suggestions regarding
Embed :
Pdf Download Link

Download Pdf - The PPT/PDF document "Guidance for Industry InternetSocial Med..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.

Guidance for Industry InternetSocial Media latforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drug s and Medical Device s DRAFT GUIDANCE This guidance






Presentation on theme: "Guidance for Industry InternetSocial Media latforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drug s and Medical Device s DRAFT GUIDANCE This guidance "— Presentation transcript:

pdf

Guidance for Industry InternetSocial Media latforms with Character Space Limitations Presenting Risk and Benefit Information for Prescription Drug s and Medical Device s DRAFT GUIDANCE This guidance - Description

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Sub ID: 5898 Download Pdf

Similar presentations

Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submission s of Interactive Promotional Media for Prescription Human and Animal Drug and Biologics DRAFT GUIDANCE This guida
Guidance for Industry Fulfilling Regulatory Requirements for Postmarketing Submission s of Interactive Promotional Media for Prescription Human and Animal Drug and Biologics DRAFT GUIDANCE This guida

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Subm

Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only
Guidance for Industry Naming of Drug Products Containing Salt Drug Substances DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only

Comments and suggestions regarding this draft document should be submitted within 90 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Sub

Guidance for Industry Interim Product Reporting for Human Drug Compounding Outsourcing Facilities nder Section B of the Federal Food Drug and Cosmetic Act DRAFT GUIDANCE This guidance document is bei
Guidance for Industry Interim Product Reporting for Human Drug Compounding Outsourcing Facilities nder Section B of the Federal Food Drug and Cosmetic Act DRAFT GUIDANCE This guidance document is bei

omments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments to httpwwwregulationsgov Subm

Guidance for Industry Distributing Scientific and Medical Publications on Unapproved New Uses Recommended Practices REVISED DRAFT GUIDANCE This guidance document is being distributed for comment purpo
Guidance for Industry Distributing Scientific and Medical Publications on Unapproved New Uses Recommended Practices REVISED DRAFT GUIDANCE This guidance document is being distributed for comment purpo

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic com ments to httpwwwregulationsgov Su

Draft Guidance for Industry and Food and Drug Administration Staff ...
Draft Guidance for Industry and Food and Drug Administration Staff ...

4 9 DRAFT GUIDANCE ) or the Office of Communication, Outreach, and Development (CBER) at 8004709 or 240 27 U.S. Department of Health and Human ServicesFood and Drug Administration Center for Device

Guidance for Industry Chronic Fatigue Syndrome Myalgic Encephalomyelitis Developing Drug Products for Treatment DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only
Guidance for Industry Chronic Fatigue Syndrome Myalgic Encephalomyelitis Developing Drug Products for Treatment DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only

Federal Register Federal Register US Department of Health and Human Services Food and Drug Administration Center for Drug Evaluation and Research CDER March 2014 ClinicalMedical 16617dftdoc 030614 brPage 2br Guidance for Industry Chronic Fatigue Sy

Guidance for Industry How to Comply with the Pediatric Research Equity Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes only
Guidance for Industry How to Comply with the Pediatric Research Equity Act DRAFT GUIDANCE This guidance document is being distributed for comment purposes only

Comments and suggestions regarding this draft docu ment should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management H

Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only
Guidance for Industry Developing Products for Weight Management DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit comments to the Division of Dockets Management HF

Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs As DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only
Guidance for Industry Expanded Access to Investigational Drugs for Treatment Use Qs As DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only

Comments and suggestions regarding this draft document should be submitted within 60 days of publication in the Federal Register of the notice announcing the availability of the draft guidance Submit electronic comments on the draft guidance to http

Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only
Guidance for Industry Complicated Intra Abdominal Infections Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being di stributed for comment purposes only

5741157455574535745357445574545746057459573765744157454574445737657459574615744757447574455745957460574495745557454574595737657458574455744757441574585744457449574545744757376574605744857449574595737657444574585744157446574605737657444